Study: Breakthrough therapies approved based on surrogate endpoints often lack postmarketing requirements
Regulatory NewsJoanne S. Eglovitch
Clinical TrialsMedical device reportingMedical DevicesPharmacovigilancePostmarketing clinical follow up (PMCF)Postmarketing requirement/postmarketing commitmentUnited States